<DOC>
	<DOCNO>NCT02328482</DOCNO>
	<brief_summary>This multi-center , randomize withdrawal , open-label , non-treatment concurrent control , parallel group study . Patients complete protocol BBCO-001 offer opportunity enter 12-month randomize withdrawal protocol .</brief_summary>
	<brief_title>Continuation Protocol Protocol BBCO-001</brief_title>
	<detailed_description>This multi-center , randomize withdrawal , open-label , non-treatment concurrent control , parallel group study . Patients complete protocol BBCO-001 offer opportunity enter 12-month randomize withdrawal protocol . Eligible patient randomize one follow treatment arm : - Treatment Arm 1 : active treatment ; continuation 30 g IV Cabaletta week additional 52 week . - Treatment Arm 2 : no-treatment concurrent control ; discontinuation IV Cabaletta follow-up 52 week . IV Cabaletta administer week patient Treatment Arm 1 . All patient , regardless treatment arm allocation , undergo safety efficacy assessment monthly site visit .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Oculopharyngeal</mesh_term>
	<criteria>1 . Adult men woman participate complete study BBCO001 2 . Clinical genetic diagnosis OPMD 3 . Able provide write informed consent participate study 4 . Able understand requirement study willing comply requirement study 1 . Pregnant lactate 2 . Currently receive anticoagulant treatment ( e.g. , warfarin ) 3 . Any lifethreatening illness , medical condition organ system dysfunction , investigator 's opinion , could compromise subject 's safety 4 . Known hypersensitivity ingredient Cabaletta IV infusion 5 . Currently participate another clinical trial ( BBCO001 ) complete interventional trial le 30 day prior plan treatment start date</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>